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Abstract 
A key part of the development of metal based Positron Emission Tomography probes is the 
chelation of the radiometal. In this review the recent developments in the chelation of four 
positron emitting radiometals, 68Ga, 64Cu, 89Zr and 44Sc, are explored. The factors that effect 
the chelation of each radio metal and the ideal ligand system will be discussed with regards to 
high in vivo stability, complexation conditions, conjugation to targeting motifs and 
complexation kinetics. A series of cyclic, cross-bridged and acyclic ligands will be discussed, 
such as CP256 which forms stable complexes with 68Ga under mild conditions and PCB-TE2A 
which has been shown to form a highly stable complex with 64Cu. 89Zr and 44Sc have seen 
significant development in recent years with a number of chelates being applied to each metal 
– eight coordinate di-macrocyclic terephthalamide ligands were found to rapidly produce more 
stable complexes with 89Zr than the widely used DFO. 
1. Introduction 
Positron Emission Tomography (PET) is a medical diagnostic technique that is 
dependent on the decay of neutron deficient nuclei that are introduced into the 
body as a radiotracer. Neutron deficient nuclei can undergo two different decay 
processes – electron capture (eqn (1)) and positron emission (eqn (2)). 
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PET exploits the second of these – the emitted positron travels a short distance 
(the average positron emitted by 18F travels 0.6 mm whereas one emitted by 68Ga 
travels 2.9 mm)1 and then undergoes an annihilation interaction with an electron 
nearby.2 The annihilation interaction results in two γ photons, each with an energy 
of 511 keV,2 being emitted simultaneously at 180° to each other.2 These two 
photons can be detected and a “line of coincidence” constructed to localise their 
source. The collection of millions of such events allows for the construction of a 
PET image (Fig. 1).3 
 
  
Fig. 1 Schematic of a PET imaging process. 1. Positron emitted from radionuclide. 2. 
Positron and electron undergo annihilation interaction and emit two photons. 3. Emitted 
photons detected.8 
 
As an imaging technique PET has a number of advantages – chief amongst these is 
its high sensitivity.4,5 A key advantage of the high sensitivity of PET is that this leads 
to a very small dose of the tracer being required – for the imaging of adults, a 
dosage of 370–740 MBq of 18F-FDG is typical,6 this corresponds to approximately 6 
pmol of the radiotracer. This is beneficial as it reduces any toxicity concerns and 
ensures that PET tracers do not saturate biological receptors. PET can also be used 
as a quantitative technique allowing for in depth study of physiological processes.7 
Recently, a number of positron emitting metal isotopes (Table 1) have begun to 
find widespread use in research8 and are moving towards medical applications. 
These PET isotopes have found favour due to their longer half-lives in comparison 
to the common organic PET isotopes 11C and 18F (Table 1) – this allows them to be 
produced off-site and transported to the imaging location, potentially allowing for 
a single production facility supplying a number of medical facilities. 
Table 1 Properties of a selection of positron emitting isotopes 
Nucleus Halflife/minutes9 Production Decay modes 
E 
 
/keV 
11C 20 14N(p, α)11C cyclotron3 β+ 100%9 39010,11 
18F 110 18O(p, n)18F cyclotron3 β+ 100%9 252,1025011 
44Sc 238 44Ti/44Sc generator β+ 100% 63212,13 
44Ca(p, n)44Sc cyclotron 
Nucleus Halflife/minutes9 Production Decay modes 
E 
 
/keV 
64Cu 762 64Ni(p, n)64Cu cyclotron8 β+ 19% 27812    
EC 41% 
 
   
β− 40%8 
 
68Ga 68 68Ge/68Ga generator8 β+ 90% 83011,12, 84410    
EC 10%8 
 
89Zr 4710 89Y(p, n)89Zr8 β+ 23% 39714    
EC 77%8 
 
 
 
 
The longer half-life of these isotopes also allows for the study of slower biological 
processes, but will prevent repeated imaging in a short space of time. The 
incorporation of ionic metal isotopes into a PET tracer is through a complexation 
mechanism, with the synthesis of the rest of the tracer being undertaken on a 
larger scale using cold chemistry. 
In order to successfully apply these metal nuclei to imaging of biological processes 
they must be chelated in an organic framework and bound to a targeting motif. 
This chelation is important for a number of reasons – the targeting of specific 
biomarkers depends on the pairing of the PET isotope with the relevant targeting 
species. If the PET tracer is not bound it will result in the signal being linked to 
blood flow and where the metal naturally accumulates (e.g. copper accumulates in 
the liver).15 Alternatively, if the metal is picked up by another biological molecule 
(e.g. gallium by transferrin)16 it may result in imaging an entirely different biological 
process. As a result, the careful selection of both chelate and targeting motif is 
important when developing an imaging agent. The selection of chelate will depend 
upon the metal used, which in turn will often be decided by the half-life required 
for the study in question. The targeting motif will depend on the receptor being 
studied and this may influence the selection of the other components of the 
tracer. 
The complexation of radiometals, such as 64Cu and 68Ga, is a key requirement for 
the development of targeted radiotracers that can be used in vivo. The chelate-
metal complex must fulfil several key requirements: 
1.1 Rapid complexation 
68Ga has a half-life of just 68 minutes – an effective tracer that uses this radio 
nuclei needs to be ready soon after it is produced. Rapid formation and 
purification of the chelate-metal complex is one of the key areas being developed 
in this field.17 
1.2 Mild complexation conditions 
Many of the targeting vectors used are susceptible to decomposition under the 
harsh conditions often required for rapid chelation. As such, high temperatures 
and extreme pH values are to be avoided. While it is possible to conjugate the 
complex to the probe after radiolabelling,18 this is typically not favoured as it 
results in a longer synthetic period overall. 
1.3 High in vivo stability 
This is essential if the radiometal is to have any specific targeting ability. The metal-
chelate complex must be stable to transmetallation by biochelators 
(e.g. metalloproteins).16 If the radiometal is displaced from the chelate complex it 
will no longer be specifically targeted. Weakly coordinated gallium is seen to 
accumulate in the skeleton,19,20 whereas copper accumulates in the liver.15,21 
1.4 Readily conjugated to targeting motifs 
In order to be used efficiently as imaging agents the radiotracers will need to 
specifically target biomarkers that indicate the disease state that is being studied. 
Whilst there are examples of chelates that will target disease states 
automatically,22,23 it is more common to use a bifunctional chelator (BFC) that can 
be conjugated to a targeting vector. Care must be taken during this step to avoid 
disrupting the chelation properties of the BFC. In some extreme cases, the 
conjugation can take place in the body.24 This review will not explore the various 
bioconjugation techniques that are used in the field of molecular imaging,25 but 
where possible will highlight successful incorporation of a site for conjugation into 
a chelate. 
Each radiometal used has its own specific requirements for optimal chelation – and 
each also has its own challenges. This review will discuss the chelation 
of 68Ga, 64Cu, 89Zr and 44Sc. The coordination of radiometals, including 68Ga, 64Cu 
and 89Zr, was extensively reviewed in 2010 by Anderson and coworkers8 and more 
recently Price and Orvig covered the coordination of a range of radiometals.17 
2. Gallium-68 
The popularity of 68Ga as a radiotracer for PET can be attributed to the 
development of the 68Ge/68Ga generator which produces 68Ga through the decay 
of 68Ge.20 This generator combines a long lived “parent” radioisotope (68Ge(IV) 
– t1/2 = 271 days) with a “daughter isotope” which has very different chemical 
properties and a half-life suitable for medical imaging (68Ga(III) – t1/2 = 68 
minutes).20 These two metals can be readily separated with the parent remaining 
on the generator column and the daughter being eluted with concentrated 
hydrochloric acid.20 This provides a non-cyclotron based route to a positron 
emitter, allowing for research and diagnosis to be undertaken at sites lacking the 
specialist cyclotron-based equipment normally required for PET. This development 
of 68Ga based PET imaging has the potential to be extremely beneficial to the field 
of medical imaging as the generator based production of 68Ga would be suitable for 
implementation in hospitals.26 Successful application of a generator produced 
radioisotope to diagnostic imaging has already been seen with the highly 
popular 99mTc isotope;27 repeating this success with 68Ga would lead to a readily 
available PET imaging. 
In aqueous solutions the only stable oxidation state of gallium is Ga(III) which is 
present as the hydrate complex under acidic conditions.20 In the pH range 3–7, this 
readily forms the complex Ga(OH)3 which is highly insoluble20 – this is a concern 
during the chelation step, which must be rapid due to the short half-life of 68Ga, as 
the transchelation of Ga(III) from Ga(OH)3 is slow.19 At physiological pH 
[Ga(OH)4]− is formed instead, which is soluble in water20 but still displays slow 
chelation kinetics due to the strong coordination of hydroxyl ligands to 
gallium.19 As such, chelation studies are usually undertaken under conditions that 
prevent the formation of Ga(OH)3 20 or in the presence of a “trapping” ligand such 
as citrate or acetate.19,20 
Many of the properties of six coordinate Ga(III) are very similar to high spin Fe(III) 
(Table 2) – this is the source of a number of issues in vivo as metalloproteins that 
typically chelate iron will also chelate Ga(III) strongly. Ga(III) shows a strong affinity 
for transferrin,16an important iron transporter in humans. This affinity defines 
much of the work that has been undertaken in the field of gallium chelation as it 
provides a standard against which a successful chelate must positively compare. 
Transchelation of 68Ga by transferrin would result in a loss of specificity and an 
accumulation of 68Ga in the liver, lungs and bone.19,20 
Table 2 Comparison of properties of Ga(III) and Fe(III) 
Property Ga(III) Fe(III) 
Ionic configuration [Ar] 3d10(ref. 8) [Ar] 3d5 
Ionic radius (6 coordinate) 6219 6519 
Log KTransferrin-M-1 20.316,19 22.819 
Property Ga(III) Fe(III) 
Log KTransferrin-M-2 19.316,19 21.519 
 
 
 
Ga(III) typically has a coordination number of 6 and complexes that fulfil this will 
have an octahedral coordination geometry.28 Due to its high charge and small ionic 
radius, the Ga(III) ion is classified as a hard Lewis acid.19 Therefore, it is expected 
that Ga(III) will display a high thermodynamic stability in complexes with hard 
Lewis basic sites containing atoms such as oxygen and nitrogen which can donate a 
lone pair of electrons to the Ga(III) ion. Carboxylate,29 phosphonate,30 and 
amine31,32 groups are ideal, and phenolate32and thiol29,33,34 groups have shown 
some success at chelating Ga(III) as well (Table 3). 
Table 3 Stability of gallium-chelator complexes 
Chelator Coordinating atoms Log KGa-L 
Transferrin NO5 20.316 
NOTA N3O3 31.08,37 
TACN-TM N3S3 34.28,38 
DOTA N4O2 26.139 
TETA N4O2 19.78,40 
EDTA N2O4 22.041 
ED2A2M N2O2S2 31.633 
HBED N2O4 37.78,42 
EC N2O2S2 31.529 
DTPA N3O3 25.141 
SBAD N4O2 28.332 
 
 
 
2.1. First generation chelates for 68Ga 
A number of cyclic chelates (Fig. 2) have been studied with 68Ga – particularly those 
based on the 14710-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA 
– Fig. 2)35 and 1,4,7-triazacyclononane-N,N′,N′′-triacetic acid (NOTA – Fig. 
2)36 frameworks. These systems have shown a high kinetic inertness, but exhibit 
poor chelation kinetics – requiring either a long complexation time or harsh 
conditions, neither of these are ideal for the development of radiotracers 
containing biomolecules. Development of these cyclic systems has aimed to 
improve the chelation kinetics without squandering the kinetic inertness of the 
resulting complex.43,44  
 
 Fig. 2 Structures of gallium chelators.  
In contrast, acyclic chelates show more favourable complex formation kinetics 
under mild conditions, but weaker complex stability under biological conditions. 
Development of acyclic chelates for 68Ga has thus had the opposite problem – 
development in this area has focused on improving complex stability whilst 
maintaining the rapid complex formation that is associated with these acyclic 
chelates.4,45 
Some conclusions can be drawn from the early work in this field (Table 3) that may 
be of benefit when considering future chelate design. The expansion of the 
azamacrocyclic ring from NOTA to DOTA and 1,4,8,11-tetraazacyclotetradecane-
N,N′,N′′,N′′′-tetraacetic acid (TETA – Fig. 2) results in a drastic drop in the stability 
of the complex formed of log 10 units from log KGa-NOTA = 31.037 to log KGa-DOTA = 
26.139 and log KGa-TETA = 19.7.58 This demonstrates the importance of a cavity size – 
ionic radius match in the thermodynamic stability of the complex formed. 
Comparing NOTA to the trismercaptotriazacyclononane chelate (TACN-TM – Fig. 2) 
shows the viability of thiol groups as chelating ligands for Ga(III) as the thiol 
containing chelate shows a higher stability (log KGa-TACN-TM = 34.2)38 than the 
carboxylic acid derivative NOTA. A comparison of two acyclic chelates, ethane-1,2-
diamine-N,N,N′,N′-tetraacetic acid (EDTA – Fig. 2)41 and N,N′-bis(2,2′-dimethyl-2-
mercaptoethyl)ethylenediamine-N,N-diacetic acid (ED2A2M – Fig. 2),33 reveals the 
same trend with the thiol containing chelate being much more stable (log KGa-
ED2A2M = 31.6)33 than the carboxylate containing chelate (log KGa-EDTA = 
22.0).41 However the phenol containing system HBED (Fig. 2) shows even greater 
stability with log KGa-HBED = 37.7.42 Despite this greater stability, few systems using 
phenols and thiols as coordinating ligands have been used to chelate gallium. This 
may be due to their low acidity in comparison to carboxylic acids (pKa ethanethiol = 
10.5, pKa phenol = 9.95, pKa Acetic Acid = 4.76)46 resulting in poor coordination 
kinetics under the acidic labelling conditions required to prevent the formation of 
Ga(OH)3. 
A comparison of N,N′-ethylene-di-L-cysteine (EC – Fig. 2, log KGa-EC = 31.5),29 in 
which the thiol containing arms are connected to the carbon back bone, and 
ED2A2M,33 in which they are connected to the amine groups, reveals little 
difference in stability – overall the same groups are donating electron density to 
the Ga(III) ion and the cavity size should be similar so this is not entirely surprising. 
2.2. Developments in 68Ga chelator design 
2.2.1. Macrocyclic chelators. Much of the work involving cyclic chelates has been 
aimed towards medical applications. The DO3Am core (Fig. 3), in which one of the 
pendant acidic groups of DOTA has been conjugated through a peptide bond, 
shows significantly lower chemical stability than the original chelate (log KGa-DOTA = 
26.1, log KGa-DO3AmBu = 24.6).39,47 This is surprising as the model for Ga-DOTA binding 
has two of the pendant arms not being directly involved in the chelation. 
Nonetheless, this system has been applied to targeted imaging,47–50 including 
applications in diagnosis of human patients. A bicyclic somatostatin agonist was 
conjugated to 68Ga-DO3Am and showed high tumour and kidney uptake. The 
tumour uptake could be blocked by injection with DOTANOC (vida infra) and the 
kidney uptake by injection with lysine to reduce background signal.48 DO3Am 
functionalised with bisphosphonate was used in an in-man study to highlight 
osteoblastic lesions caused by prostate cancer metastases.47 DOTATOC, DOTANOC 
and DOTATATE are all derivatives of DO3AM with specific peptide sequences for 
the targeting of somatostatin receptors. DOTATOC has the sequence D-Phe-Cys-
Tyr-D-Trp-Lys-Thr-Cys-Thr(OH), DOTANOC has the sequence D-Phe-Cys-NaI-D-Trp-
Lys-Thr-Cys-Thr(OH) and DOTATATE has the sequence D-Phe-Cys-Tyr-D-Trp-Lys-
Thr-Cys-Thr. 68Ga complexes of all three have been applied in a number of medical 
studies.51–55  
  Fig. 3 Structures of novel cyclic gallium chelators.  
NOTA was conjugated from the macrocyclic carbon backbone in multiple studies – 
the labelling properties and stability of these complexes were found to be good, 
with labelling proceeding at room temperature in 10 minutes.56 Minimal transfer 
to transferrin was seen inin vitro tests with these chelates.56 When functionalised 
with nitrobenzene the complex showed high retention in the kidneys and the 
bladder, but also showed rapid clearance from blood, heart and muscle.57 When 
conjugated to c(RGDyK) this system showed no degredation over 2 hours, and only 
2% over 3 hours, in the presence of transferrin at 37 °C and pH 6.9.58 When a 
bisphosphonate functionality was applied to NOTA through C-functionalisation of a 
pendant arm, the resulting complex showed good blood clearance and some 
uptake in the skeleton 2 hours after injection.59 The stability of this system was 
very high, 95% of the original complex remained after 3 hours in rat plasma. This 
was applied to the imaging of osteolytic lesions in mice59 as well as being applied 
to an in man study47showing high target uptake and low soft tissue uptake. 
A commonly used NOTA derivative is NODAGA (Fig. 3)60 showing similar 
complexation kinetics to NOTA,49,50,61,62 NODAGA has been chelated to a number 
of different peptides including c(RGDyK), c(RGDfK) and NaI3-octretide (NOC) and 
also to bisphosphonate.49,50,59,61,62 These derivatives showed good stability, due to 
their NOTA core, and high target uptake in small mammal models, with 68Ga-NOTA-
LM3 showing a 10 fold greater somatostatin receptor uptake than the 
equivalent 68Ga-DOTA-LM3 system.50 
The adaptation of NOTA to include phosphonic acids and phosphinates to form the 
TRAP system (Fig. 3) by Notni and coworkers30,63 led to a chelate that could be 
labelled with 68Ga across a range of conditions. Of particular interest is the 
potential to label under extremely acidic conditions, such as those of the eluent 
from the 68Ge/68Ga generator. This is possible due to the low pKa of the phosphinic 
acids (pKa < 1) used in the TRAP chelates.63 TRAP-Pr, in which the phosphinate is 
capped with butanoic acid, equilibriated very slowly. After weeks of equilibriation 
this gave a stability constant, log KGa-TRAP-Pr = 26.2, however on the time scale of 68Ga 
imaging the value was approximated to be log KGa-TRAP-Pr = 35, which is higher than 
the reported value for Ga(III)-NOTA (log KGa-NOTA = 31.0).37 The proposed reason for 
this high stability is the increased negative charge of the [Ga(III)-TRAP]3− species 
relative to Ga(III)-NOTA – this would hinder the approach of hydroxide anions and 
therefore decomplexation of the Ga(III) ions. 
Amide coupling performed on the pendant carboxylate groups of TRAP-Pr allowed 
the conjugation of c(RGDyK) to this chelate without affecting the binding 
site.62,64 Notni and coworkers demonstrated that conjugation using a copper 
catalysed “click” mechanism was a feasible means of conjugating the TRAP chelate 
to peptides.65 While the copper catalyst used was bound by the TRAP chelate, this 
could be removed using a more thermodynamically stable chelator prior to 
radiolabelling.65 A compound with both rhodamine and c(RGDyK) conjugated and a 
third with biotin chelated were also formed.30 The tris-RGD compound showed a 
much higher affinity for αvβ3 receptors than 68Ga-NODAGA-RGD or 18F-galacto-RGD 
with the inhibition concentration of TRAP-(RGD)3 being an order of magnitude 
lower.64 A multimodal PET-MRI agent based on the TRAP chelate has been 
developed in which DOTA was attached to the end of the pendant arms. 
Complexation with gadolinium resulted in both the TRAP and DOTA sites being 
occupied by Gd(III). Ga(III) could displace the Gd(III) in the central TRAP site 
relatively easily, forming the [Ga][Gd]3[TRAP-(HMDA-DOTA)3] complex. For the 
purposes of radiolabelling, the central Gd(III) ion was removed by addition of DTPA 
before addition of 68Ga to form [68Ga][Gd]3[TRAP-(HMDA-DOTA)3].66 Due to the 
significant difference in sensitivity of MRI and PET, 20 μmol of [Gd]4[TRAP-(HMDA-
DOTA)3] was injected along with 0.8 nmol of the [68Ga][Gd] complex during rat 
studies in which both PET and MRI images could be collected with colocalised 
regions of contrast.66 
A derivative of the TRAP chelate in which the pendant arms are different is NOPO 
(Fig. 3). In this asymmetric chelate two of the arms are methyl alcohol groups 
whereas the third is a butanoic acid species67 This had little effect on the stability 
and coordination properties of this species compared to TRAP – perhaps not 
surprising as both TRAP-OH and TRAP-Pr showed good properties in both of these 
areas – however this asymmetric functionalization allows for the selective 
conjugation of the carboxylic acid arm to give a mono-peptide chelate.44,68 This 
allows for the direct comparison of this chelate to other mono-peptides, such as 
DOTATOC, and also has the potential to allow a multimodal imaging agent to be 
made through selective functionalization of the carboxylic and alcohol arms. RGD-
chelated68Ga-NOPO was shown to have high hydrophilicity and cleared rapidly 
from the blood and organs of mice.44 Chelation to NaI3-octretide to create NOPO-
NOC yielded a gallium complex that showed high tumour uptake and low organ 
uptake in rats.68 
PCTA (Fig. 3) incorporates pyridine into the macrocycle of DOTA in place of a 
secondary amine.58 PCTA-RGD was labelled with 68Ga in under 30 minutes at room 
temperature and is reasonably stable to transferrin, with 10% of 68Ga being lost in 
4 hours.57Ga-PCTA-RGD displayed a similar biodistribution to Ga-NOTA-RGD, but 
exhibited lower kidney uptake and a higher tumour-to-kidney ratio – this is 
encouraging for future work as this will improve the contrast of any collected 
images. 
2,2′,2′′-(1-Oxa-4,7,10-triazacyclododecane-4,7,10-triyl)triacetic acid (oxo – Fig. 3), 
in which one of the aza nitrogens of DOTA is replaced with an oxygen atom, was 
far less stable and showed significant degredation in the presence of transferrin.57 
Typically used with copper and other metals, Ma and coworkers used 
(c(RGDyK)NH)2Sar with 68Ga to some success.69 Radiolabelling required 30 minutes 
incubation at 80 °C, but the resultant complex was relatively stable to transferrin 
after incubation for 2 hours, with only 11% of the complex degrading (Table 4). 
Table 4 Stability and radiochemical yield (RCY) of macrocyclic chelates for 68Ga 
chelation 
Chelator Log KML Labelling conditions RCY/% 
DOTA 26.139 85 °C, pH 4.0, 30 minutes, 100 μM 9570 
DO3Am 24.639 80 °C, pH 4, 5 minutes, 1 mM 10071 
Chelator Log KML Labelling conditions RCY/% 
NOTA 31.08,37 RT, pH 3.5, 10 minutes, 10 μM 9556 
NODAGA 
 
RT, pH 4.0, 10 minutes, 3 μM 9747 
TRAP-OH 23.343 RT, pH 3.3, 5 minutes, 3 μM 8830 
TRAP-Ph — RT, pH 3.3, 5 minutes, 3 μM 8030 
TRAP-Pr 26.263 30 °C, pH 3, 5 minutes, 2.6 μM 9563 
60 °C, pH 1, 5 minutes, 2.6 μM 
TRAP-(HMDA-DOTA)3 — 95 °C, pH 2, 5 minutes, 6.8 μM 9766 
NOPO 25.044,68 95 °C, pH 2.8, 5 minutes, 0.1 μM 10044,68 
NOPO-RGD — 100 °C, pH 1.8, 5 minutes, 1 μM 94 
MA-NOTMP — 95 °C, pH 2.5, 5 minutes, 0.1 μM 10072 
PCTA-C-Bn-p-NO2 — RT, pH 4–5, 5 minutes, 1 mM 98.957,58 
Oxo-C-Bn-p-NO2 — RT, pH 4–5, 5 minutes, 1 mM 98.557 
(NH2)2sar — 85 °C, 30 minutes, 18 μM 10069 
L1 — 170 °C (150 W μwave), 7 minutes, 6.1 μM 6923 
L2 — 170 °C (150 W μwave), 7 minutes, 6.6 μM 4923,73 
L3 — 300 W μwave, 5 minutes, 0.1 mM 8223 
L4 — 300 W μwave, 5 minutes, 0.1 mM 8323 
L5 — 300 W μwave, 7 minutes, 0.1 mM 4223 
TeMP — 100 °C, 45 minutes, 0.8 mM 9074 
TriMPN3 — 110 °C, 7 minutes, 0.06 mM 9575 
TriMPEG — 110 °C, 7 minutes, 0.06 mM 9575 
TFPP — 100 °C, pH 5.5, 60 minutes, 160 μM 9976 
NOTAMBP — 95 °C, pH 4.2, 10 minutes, 21 μM 10077 
NO2APBP — 60 °C, pH 4.2, 10 minutes, 21 μM 10077 
TAFC — RT, pH 3.9, 15 minutes, 3 μM 10078-80 
FOXE — 80 °C, 20 minutes 9579,80 
FSC — RT, pH 4, 15 minutes, 1 μM 9581,82 
 
 
The compound displayed high tumour uptake and low retention in organs, except 
for the excretion pathway through the kidneys. 
Seeking to take advantage of the similarities of Ga(III) and Fe(III), Rösch and 
coworkers used a series of tetrapyrrole porphyrins to chelate 68Ga.23 Although 
radiolabelling using conventional heating methods was poor (<20%), microwave 
assisted radiolabelling of both water soluble and lipophilic tetrapyrroles was more 
successful, with yields greater than 80% being reported for two of the chelates 
tested after 5 minutes of radiolabelling.23 Overall, the lipophilic tetrapyrroles L3 and 
L4 showed greater radiolabelling and stability to transchelation and 
transmetallation, with >90% of the complex remaining intact after 2 hours in the 
presence of excess transferrin, than the hydrophilic L1. Indeed, in human serum 
L1 was so unstable that it was indistinguishable from free 68Ga – although this was 
suggested to be due to decomposition of the chelate in serum.23 Preliminary 
imaging studies using L1 in a rat model demonstrated the potential of these 
systems for targeting tumours – with a tumour to tissue ratio of 2 being achieved 
after allowing the system to equilibriate through tracer washout from the non-
target tissues.23 
Banerjee and coworkers recently demonstrated a highly stable 68Ga-porphyrin 
system based on 5,10,15,20-tetra(4-methylpyridyl)porphyrin (TeMP).74 Although 
high temperatures (100 °C) and ligand concentrations (0.8 mM) were required to 
achieve a 90% RCY, the resulting complex was stable to human serum, with 98% 
remaining intact after 2 hours.74 Boyle and co-workers used a similar chelate, 
TriMP, which was functionalised with an azide group to conjugate the porphyrin to 
a peptide.75 Again, microwave irradiation was used to promote chelation of 68Ga by 
the porphyrin, with complexation being completed within 7 minutes when heated 
to 110 °C.75 The polyfluorinated porphyrin, TFPP, was radiolabelled by Fazaeli and 
co-workers76 – the resulting complex showed high stability, with 99% remaining 
after 5 hours under physiological conditions.76 However, heating at 100 °C for 60 
minutes was required for labelling of this system.76 
A number of siderophores (Fig. 3), have been tested for their suitability as Ga(III) 
chelators. As Fe(III) binding compounds it can be expected that these chelators will 
also bind Ga(III) efficiently due to their similar properties (Table 2). After testing a 
panel of siderophores, Decristoforo and coworkers found that triacetylfusarine C 
(TAFC – Fig. 3) and ferrooxamine E (FOXE – Fig. 3) were the most suitable for 
application to gallium chelation.79,80 While the majority of siderophores tested 
showed rapid gallium uptake under mild conditions, the resulting complexes 
formed by these two were highly stable (>95%) to a range of metabolic conditions 
– and most importantly survived in vivo when tested in rats.79,80 Uptake was 
tested in vitro with a strain of fungi, Aspergillus Fumigatus, which lacked 
siderophore biosynthesis and as such relied on external siderophores as a source 
of iron.79,80 Both FOXE and TAFC were taken up, as was Fusarine C (FSC – Fig. 
3).79,80 Later studies on Fusarine C demonstrated that it also rapidly chelated 
gallium and showed suitable stability to PBS, EDTA and human 
serum.81 Decristoforo et al. noted that FSC was less stable to iron chloride 
transmetallation and DTPA transchelation than TAFC.78 To assess the effect that 
acylation of the pendant amine of FSC had on the stability of the resultant 
complex, and to use this as a method of conjugating FSC to a targeting motif, they 
tested two – FSC-(AcPro)3 and FSC-(RGD)3.82 Both derivatives could be rapidly 
labelled and showed high stability to human serum.82 
Overall the improvements made in the field of cyclic chelators for 68Ga are 
relatively mild – the promising TRAP and NOPO systems being comparable to 
NOTA for labelling efficiency, although the remote carboxylic functionalities of 
TRAP-Pr allow for easier conjugation of a targeting functionality. These chelates are 
however a significant improvement over the widely used DOTA for complexation 
of 68Ga, in terms of complexation kinetics and the stability of the resulting complex. 
Ultimately, NOTA based chelates are still the superior cyclic chelates for 68Ga – 
further work to improve upon the design of new chelates will be needed if NOTA is 
to be replaced. 
2.2.2. Non-macrocyclic chelators. In recent years there has been a shift towards 
acyclic ligands for the chelation of 68Ga. This movement away from macrocyclic 
chelates is due to the aims of rapid radiolabelling under mild conditions – room 
temperature and neutral pH – and at a low ligand concentration. 
Developed by Orvig and coworkers, H2dedpa (Fig. 4) combines amine, pyridine and 
carboxylic acid functionalities to bind Ga(III) with a high stability.4 The H2dedpa 
chelate and its derivatives rapidly coordinate 68Ga, with quantitative radiochemical 
yields being reported at room temperature in 10 minutes.4 This ligand shows high 
stability to transferrin over 2 hours, although functionalization of the amines 
results in a significant loss of stability.4,83 Labelling of this chelate through the 
carbon backbone provides a route to conjugation without loss of stability – the C-
c(RGDyK) conjugate complex was 92% stable to transferrin after 2 hours. The 
pyridine ring offers an alternative site for functionalization and manipulation of 
both this and the N-functionalisation site allowed for the lipophilicity of the 
resulting complex to be tailored.84 The most lipophilic compounds showed greater 
stability to transchelation by transferrin84 – Orvig et al. speculated this may be due 
to the polar nature of the transferrin binding site. The general biodistribution for 
this system is a rapid clearance from background tissue and excretion through 
kidneys. On the otherhand, the most functionalised derivatives were shown to 
accumulate in the liver due to their increased aromaticity.84 RGD conjugates 
showed high tumour uptake but had slow blood clearance.4,84,85 
 
  Fig. 4 Structures of novel non-macrocyclic gallium chelators.  
In contrast to other N-conjugates, a series of complexes conjugated to a 
nitroimidazole moiety showed relatively high stability to transferrin 
competition,22 in addition to being suitable for hypoxia imaging. However, this 
series of chelates could only be labelled at ligand concentrations greater than 
10−4 M,22 much higher than the unconjugated chelate which is reported to 
complex 68Ga at ligand concentrations as low as 10−7 M.4 
Although 99% stable to transferrin over 2 hours,4 when tested for transmetallation 
in human serum the 68Ga-dedpa complex showed only 78% stability.86 To improve 
the stability of the complex, the Orvig group increased the rigidity of the backbone 
by incorporating a cyclohexyl group.86 The resulting 68Ga-CHXdedpa (Fig. 4) 
complex showed a 90% stability to human serum, although it showed a reduced 
radiolabelling at lower ligand concentrations.86 H2azapa (Fig. 4), designed to make 
conjugation easier through a CuAAC “click” reaction, showed a reduced clearance 
in line with other N-functionalised H2dedpa complexes and only a 52% stability to 
transferrin over 2 hours.87 
Originally used with manganese to create an MRI relaxation based contrast 
agent,88 AAZTA (Fig. 4) has also been used for coordination of Ga(III).89–91 Parker 
and coworkers showed that this system could be used to complex 68Ga very rapidly 
under mild conditions. Forming a gallium complex with greater stability than Ga-
transferrin, this system was applied in rats and showed only bladder and kidney 
uptake after 25 minutes. 
Vologdin and coworkers applied Ga-AAZTA to a probe that could measure pH in 
vivo by combining MRI and PET properties.92 The multimodal probe was 
constructed by conjugating a protected AAZTA chelate through an arylsulfonamide 
bridge to a protected DO3A moiety.92 Selective deprotection of DO3A allowed for 
complexation of Gd(III) by the DO3A chelate; after deprotection of AAZTA the 
probe could be used to coordinate Ga(III) with the future potential for 
radiolabelling. The resultant Gd(III)-68Ga species would be used to measure pH due 
to the pH dependent relaxitivity effect of gadolinium being quantifiable through 
the use of PET imaging to determine concentration, although radiolabelling of this 
complex has not yet been undertaken. 
AAZTA was reported to form multiple complexes with Ga(III) by Parker et al.91 This 
was speculated to be due to conformational changes in the seven membered ring. 
The formation of multiple complexes was still seen when DATAM (Fig. 4) was used 
as the chelator, despite its reduced number of coordination sites.91 In contrast, 
increasing the steric hindrance to ring inversion by replacing a methyl group with a 
phenyl ring (DATAPh and DATAPPh) resulted in a single complex being 
formed.90,91,93 While the formation of 68Ga-DATA complexes was slower than that 
of 68Ga-AAZTA complexes,91 the formation of a single complex is important for 
further characterisation of the system and wider acceptance of the ligand system. 
In addition, the additional products formed by AAZTA when complexing Ga(III) 
were less stable than the products of DATA chelation – the Ga(III)-DATA complexes 
were stable to DTPA, iron and transferrin over 2 hours,91 and appeared to be 
biologically inert as activity was seen in only the kidneys and bladder of injected 
rats.91 In a labelling study,94 the DATA chelators have been reported to 
complex 68Ga(III) across a range of conditions suitable for labelling – with a 97% 
yield at room temperature in 1 minute being achieved by 3.6 μM of chelator.94 
A pair of N4O2 chelators, H2Lpz*,NH and H2Lpy,NH (Fig. 4), were synthesised by Paulo 
and coworkers with either a pyridine or pyrazol arm.95 The 68Ga-Lpz*,NH complex 
showed poor stability, but the 68Ga-Lpy,NH complex was stable to transferrin over 48 
hours. This system showed fast blood clearance in mice and negligible bone 
uptake. Analysis of blood serum and urine samples confirmed that the 68Ga 
complex had not degraded in vivo. However, this system is hampered by the high 
temperatures (85 °C) required for complexation (Table 5).95 
Table 5 Stability and RCY of novel non-cyclic chelators for 68Ga 
Chelator Log KGa-L Labelling conditions RCY/% 
H2dedpa 28.114 RT, pH 4.5, 10 minutes, 0.1 μM 955 
H2CHXdedpa 27.6186 RT, pH 4, 10 minutes, 10 μM 9986 
H4AAZTA 22.289,90 RT, pH 4, 1 minute, 1 μM 9791 
H3DATAM — RT, pH 5, 5 minutes, 3.6 μM 9894 
H3DATAP — RT, pH 5, 5 minutes, 3.6 μM 9694 
H3DATAPh — RT, pH 5, 5 minutes, 5 μM 9994 
H3DATAPPh — RT, pH 7, 15 minutes, 3.6 μM 9894 
H2Lpz*,NH — 85 °C, pH 5, 15 minutes, 1 mM 2595 
H2Lpy,NH — 85 °C, pH 5, 15 minutes, 60 μM 9595 
CP256 — RT, pH 6.5, 5 minutes, 10 μM 9845 
H2ATSMNa — 90 °C, 30 minutes, 200 μM 7097 
BADED-2 — 80 °C, pH 4.3, 10 minutes, 40 μM 9798 
BADED-3 — 80 °C, pH 4.3, 10 minutes, 30 μM 9898,99 
BADED-4 — 80 °C, pH 4.3, 10 minutes, 50 μM 9898,99 
BADED-5 — 80 °C, pH 4.3, 10 minutes, 40 μM 9798,99 
BADED-6 — 80 °C, pH 4.3, 10 minutes, 40 μM 9898 
BADED-7 — 80 °C, pH 4.3, 10 minutes, 30 μM 9798 
BADED-8 — 80 °C, pH 4.3, 10 minutes, 30 μM 9898,99 
BADED-9 — 80 °C, pH 4.3, 10 minutes, 30 μM 9898,99 
MFL3.MZ — 80 °C, pH 4.3, 10 minutes, 80 μM 5599 
 
 
Originally an iron chelator, CP256 (Fig. 4), which utilises hydroxypyridone units to 
chelate 68Ga was shown to have promising properties.45 This chelate bound 68Ga 
rapidly under mild conditions – near quantitative yields were achieved in 10 
minutes at room temperature and pH 6.5 with only 10 μM of ligand.45 This 
matches well with the performance of NOTA, and at lower chelate concentrations 
CP256 outperforms NOTA – with a RCY approximately double that of NOTA at 1 
μM.45 This rapid radiolabelling is accompanied by a high kinetic stability – 68Ga-
CP256 showed significant stability to transferrin with no transchelation seen after 
4 hours incubation.45 Conjugation to the protein C2Ac was achieved through a 
maleimide derivative of CP256.45 This protein conjugate retained the in 
vitro calcium binding properties of the parent protein, and in a small mammal 
study the complex was found only in excretory organs45 supporting the high 
stability previously seen. Two isothiocyanate containing derivatives have also been 
developed, conjugation through the isothiocyanate functionality to c(RGDfK) 
resulted in a probe that showed high stability in vivo with no bone uptake being 
observed and a receptor dependent tumour uptake being displayed.96 
Dilworth et al.97 applied the thiosemicarbazonate, H2ATSM (Fig. 4), to 68Ga 
chelation with limited success – the resulting complex was poorly soluble in water 
and highly unstable in foetal bovine serum. This instability is likely due to the 
partial coordination of gallium by the four coordinate ligand – the complex that 
forms includes a chloride ion coordinated to the Ga(III) centre. Adaptation of the 
chelate to incorporate a naphthalene backbone (Fig. 4), increased stability 
significantly, although degradation from the chloride complex to the hydroxide 
complex was seen over time.97 This hydroxide complex led to cleavage of one of 
the thiosemicarbazone arms. The H2ATSMNap ligand was not isolated – however the 
zinc complex could be. Displacement of the zinc ion by 68Ga was used for 
radiolabelling in ethanol, achieving a 70% yield after 30 minutes reaction at 
90 °C.97 
Rösch and coworkers applied a range of Schiff ligands with the BADED backbone to 
the complexation of 68Ga(III).98,99 All ligands were able to rapidly complex 68Ga at 
elevated temperatures except for the most sterically hindered ligand MFL3.MZ.99 
The field of acyclic 68Ga chelators has developed significantly in recent years – a 
number of new, highly promising chelators that are comparable to NOTA in terms 
of radiolabelling kinetics and kinetic inertness of the resulting complex have been 
reported. The AAZTA89,91 and DATA94 families of chelates show extremely rapid 
complexation at room temperature (1 minute and 3 minutes respectively) – 
although this system has not yet been tested for its radiolabelling efficiency after 
conjugation to a targeting probe. 
The importance of selecting the conjugation site carefully was highlighted by 
Orvig et al. and their work with the H2dedpa chelator – chelation through one of 
the amine binding sites had unpredictable consequences for the stability of the 
resulting complex.4,100Circumventing this by implementing an alternate, easily 
accessible, chelation site may see the H2dedpa system becoming more widely 
adopted. The impressive CP256 chelator45 shows extremely high stability to 
transchelation by transferrin and initial studies in vivo are promising. 
2.3. Gallium conclusions 
The work undertaken in recent years has moved gallium chelates much closer to 
widespread use. The acceptance and application of 68Ga-DOTA derivatives to 
medical studies is promising and demonstrates the value of this isotope as a 
diagnostic tool.51–55 
The increased affinity seen for 68Ga-TRAP-(RGD)3 64 when compared to 68Ga-DOTA-
RGD is promising for the future of this system – if this increase in affinity is 
transferable to other bioconjugates then the use of TRAP chelates instead of DOTA 
chelates would be highly favourable. The separation of conjugation functionality 
from the binding core also makes it easier to create a variety of different tracers 
with specific applications without increasing transchelation. 
The acyclic chelates AAZTA91 and CP25645 are both highly promising for future 
development. While AAZTA appears to form multiple complexes,91 the DATA 
derivatives eliminate this problem whilst retaining the rapid (<3 minute) 
complexation of 68Ga.94 CP256 has displayed very impressive gallium complex 
stability to transferrin alongside rapid 68Ga complexation at low concentrations of 
ligand.45 Further development of these two ligand systems will highlight the value 
of acyclic chelators in the future of 68Ga PET. 
The use of preformed coordinating centers appears to be key to the production of 
an inert metal-chelate complex as shown by the kinetic stability of NOTA, 
tetrapyrrole and DATA complexes, and the improved stability of the more 
rigid 68Ga-CHXdedpa complex in comparison to the complex formed from the linear 
H2dedpa system in human serum. The use of a preformed coordinating face in the 
DATA ligands offers an inert alternative to the macrocyclic systems, such as NOTA, 
that can withstand transferrin competition and also rapidly complex 68Ga. 
Incorporation of this style of preformed core into future chelates may allow for 
improved retention of 68Ga in vivo without negatively impacting upon 
radiolabelling kinetics. 
Interestingly, CP256 and H2Lpy,NH, which do not have a rigid preformed structure, 
also display high inertness to transferrin competition. This may be due to the 
branched nature of these chelates, rather than linear, resulting in reduced degrees 
of freedom and therefore less entropic drive to decomplexation. 
3. Chelating copper-64 
A number of copper isotopes emit positrons; 64Cu (t1/2 = 12.7 hours) has the second 
longest half-life of the metal based PET isotopes.9 This is significantly longer than 
the traditional PET isotopes 11C (20 minutes) and 18F (109 minutes). As such 64Cu 
has the potential to be applied to targeting motifs that have a longer blood lifetime 
such as antibodies.101 
64Cu is produced in a cyclotron by bombarding an enriched nickel target (64Ni(d, 
2n)64Cu or 64Ni(p, n)64Cu).102 Cu(II) can form stable complexes with coordination 
numbers from 4 to 6.8 The resulting complexes have varied geometries due to the 
variation in coordination number, those with a coordination number of 6 typically 
having an octahedral geometry which may undergo Jahn–Teller distortion. Under 
physiological conditions, Cu(II) can be reduced to Cu(I) – this has the potential to 
cause demetallation of the complex. As such, it is important for a chelator selected 
for use with 64Cu to be able to complex both Cu(I) and Cu(II) or to stabilise Cu(II) to 
prevent reduction. This property of copper can be exploited for imaging of hypoxia 
as demonstrated by Dearling and coworkers.103 Whilst the reductive potential of a 
complex can be used as a measure of the potential in vivo stability, little has been 
done to design chelates specifically based on this property. As a result, and due to 
the poor translation of this property across the metals investigated, the reductive 
potential has not been extensively explored in this review. 
Copper is the third most abundant trace metal in the body, after iron and zinc.21 As 
such, a number of proteins incorporate copper104 and could potentially compete 
with a chelate to bind 64Cu. Cu(II) ions administered directly into the blood stream, 
by I.V. or orally, are initially bound by albumin, a copper transport protein.15 This 
leads to rapid clearance of 64Cu from the blood105 to the liver.15 Ceruloplasmin 
accounts for 65–70% of the copper in human serum.10464Cu deposited in the liver 
by albumin is incorporated into ceruloplasmin and then returns to the 
bloodstream15 where it is slowly transferred to other organs.21 
3.1. First generation 64Cu chelators 
Macrocycles were shown to be more stable chelators of copper than their acyclic 
counterparts in 1969 when Cabbiness et al. compared 5,7,7,12,14,14-hexamethyl-
1,4,8,11-tetraazacyclotetradecane (tet-a – Fig. 5) and N,N′-di(2-aminoethyl)-
propylenediamine.106 While both ligands share the same coordination sites and 
spacing, the macrocycle tet-a forms a much more stable complex when binding to 
copper. Accordingly, the majority of chelates studied for the binding of 64Cu have 
been macrocyclic in nature.  
  Fig. 5 Structure of copper chelators.  
A comparison of the stability of three common macrocyclic chelates in 
radiochemistry, NOTA, DOTA and TETA (Fig. 3) suggests that DOTA provides the 
optimum stability for a copper complex due to its highest stability constant 
(21.63,107 22.63 (ref. 108) and 20.49 (ref. 109) respectively). However a 
comparison of the halflife of the Cu-DOTA and Cu-TETA complexes under acidic 
conditions suggests a greater stability for TETA under these conditions (Table 
6).110 Interestingly, 1,4,8,11-tetraazacyclotetradecane (cyclam – Fig. 5) has a much 
higher stability constant114 than TETA, despite having fewer coordination sites – 
however a comparison of the stability of these complexes in acidic conditions again 
reveals Cu(II)-TETA to have a greater stability.110 
Table 6 Stability of copper-chelate complexes and radiolabelling conditions 
Chelator Log KCu-L Acid halflife 
Labelling 
conditions RCY 
tet-a 28.0106 1.1 hours (5 M 
HCl, 90 °C)110 
  
N,N′-Di(2-
aminoethyl)propylenediamine 
23.9111 
   
EDTA 18.9107 
   
NOTA 21.63107 <3 minutes (5 M 
HCl, 30 °C)8 
  
Chelator Log KCu-L Acid halflife 
Labelling 
conditions RCY 
Cyclen 24.60112 9.53 minutes (5 
M HClO4, 
25 °C)112 
  
DO2A 18.9108 
 
RT, pH 5.5, 120 
minutes, 5 mM 
100108 
DO3A 22.87113 
   
DOTA 22.63108 <1 minute (5 M 
HCl, 
90 °C)110 28.1 h 
(5 M HClO4, 
25 °C)112 
RT, pH 5.5, 120 
minutes, 5 mM 
99108 
DO2P 28.7108 
 
90 °C, pH 6.5, 4 
hours, 2 mM 
97.8108 
DO3P 26.9108 
 
RT, pH 6.5, 120 
minutes, 2 mM 
96.6108 
DOTP 26.2108 
 
RT, pH 6.5, 120 
minutes, 2 mM 
96.9108 
CB-DO2A 
 
<2 minutes (5 M 
HCl, 30 °C)110 
  
Cyclam 27.2114 2.7 days (5 M 
HCl, 30 °C)110 
  
CB-Cyclam 27.1114 18.5 days (5 M 
HCl, 30 °C)110 
75 °C, (4.7% 1 N 
NaOH/EtOH), 60 
minutes, 10 mM 
99114 
TETA 20.49109 3.5 days (5 M 
HCl, 30 °C)110 
  
TE2P 26.5109 6.7 months (5 M 
HClO4, 25 °C) 
  
TETP 26.6115 
   
CB-TE2A 
 
154 hours (5 M 
HCl, 90 °C)110 
95 °C, pH 8.0, 2 
hours, 10 μM 
95116 
 
 
 
The incorporation of an ethylene cross bridge into the cyclam ring results in a 
drastic increase in stability of the resultant copper complex. The 1,4,8,11-
tetraazabicyclo[6.6.2]hexadecane (CB-cyclam – Fig. 5) copper complex has a 
halflife in acidic media six times longer than cyclam (Table 6),114 and the 1,4,8,11-
tetraazabicyclo[6.6.2]hexadecane-1,8-biacetic acid (CB-TE2A –Fig. 5) copper 
complex has a halflife over two thousand times longer than TETA (Table 6).114 The 
same is not true for 1,4,7,10-tetraazabicyclo[5.5.2]dodecane-1,7-biacetic acid (CB-
DO2A – Fig. 5) which forms a less stable complex than DOTA (Table 6).114 
To investigate the effect of an overall negative charge on the biodistribution of 
macrocyclic complexes, Sun et al. synthesised and tested a range of cyclen 
derivatives with phosphonic acid pendant arms to compare to the previously 
tested carboxylic acid based chelates.108 Methylphosphonic acid derivatives of 
cyclen (Fig. 5) showed an increased stability when compared to the equivalent 
acetic acid chelates for the coordination of copper (log KCu-DOTA = 22.63, log KCu-DOTP = 
26.2, log KCu-DO3A = 22.87, log KCu-DO3P = 26.9, log KCu-DO2A = 18.9, log KCu-DO2P = 
18.7).113,114 These phosphinic acid containing complexes also showed high bone 
uptake making them potential bone-targeting imaging agents.108 Increased stability 
was also seen for TETP (1,3,8,11-tetraazacyclotetradecane-N,N′,N′′,N′′′-
tetra(methylphosphonic acid) – Fig. 5 – log KCu-TETP = 26.6)115 in comparison to TETA 
(log KCu-TETA = 20.49).109 
3.2. Current developments in copper chelate design 
3.2.1. Macrocyclic 64Cu chelators. Due to the stability of CB-TE2A in comparison to 
TETA, a number of cyclam derivatives with different crossbridge motifs have 
recently been investigated. One of the most significant incorporates a propylene 
cross bridge instead of an ethylene cross bridge to form PCB-TE2A (Fig. 6).119 The 
Cu-PCB-TE2A complex displays remarkable stability under acidic conditions; it is 
reported that no degradation was seen after seven days in 12 M HCl at 90 °C. This 
is superior to CB-TE2A which has a halflife of 6.4 days in 5 M HCl at 
90 °C.110 Radiolabelling of PCB-TE2A also proceeded faster and at a lower 
temperature than that of CB-TE2A (Table 7).116 The 64Cu-PCB-TE2A complex 
showed no signs of decomplexation after 24 hours in rat serum at 37 °C, and 
showed rapid clearance when tested in rats.119 Extension of the cross-bridging link 
also significantly improved the kinetic stability of CB-DO2A; in 2011, Anderson and 
coworkers applied a propyl cross-bridged DO2A ligand, C3B-DO2A, to the 
complexation of Cu(II).124Although this ligand required microwave heating under 
acidic conditions to promote complexation, the resulting complex, 64Cu-C3B-DO2A, 
showed much higher kinetic stability (t1/2 = 1.1 days, 12 M HCl, 90 °C)124 to acid 
promoted decomplexation than the ethyl cross-bridged analogue CB-DO2A (t1/2 = 
<2 minutes, 5 M HCl, 30 °C).110  
  Fig. 6 Structures of new copper macrocyclic chelators.  
Table 7 Stability and radiolabelling conditions of novel copper-chelate complexes 
Chelator Log KCu-L Acid halflife Labelling conditions RCY 
Pycup2A 
 
2.7 hours (5 M HCl, 
90 °C)117 
70 °C, pH 7.4, 15 minutes, 10 μM 100117 
Pycup1A1Bn 
 
1.5 hours (5 M HCl, 
90 °C)117 
70 °C, pH 7.4, 15 minutes, 10 μM 100117 
Pycup2Bn 
 
20.3 hours (5 M HCl, 
90 °C)117 
70 °C, pH 7.4, 15 minutes, 10 μM 100117 
DOTPI 23.1118 
 
20 °C, pH 3, 5 minutes, 10 μM 90118 
PCB-TE2A 
 
>7 days (12 M HCl, 90 °C)119 70 °C, pH 8, 60 minutes, 5 mM 100119 
TRAPPr 19.165 2 hours (pH 3.5, 25 °C)65 25 °C, pH 3, 5 minutes, 1 μM 100120 
Chelator Log KCu-L Acid halflife Labelling conditions RCY 
NOPO 
  
25 °C, pH 3, 5 minutes, 1 μM 100120 
CBTE2P 
 
3.8 hours (5 M HCl, 
90 °C)121 
RT, pH 8.1, 30 minutes, 26.5 μM >95121 
CBTE1A1P 
 
6.8 hours (5 M HCl, 
90 °C)121 
RT, pH 8.1, 30 minutes, 26.5 μM >95121 
PCB-TE1A1P 
 
8 days (12 M HCl, 90 °C)122 60 °C, pH 8, 1 hour, 25 μM 95122 
PCBTE2P 
 
>2 days (5 M HCl, 90 °C)123 90 °C, pH 8, 10 minutes, 5 mM 100123 
C3B-DO2A 
 
1.1 day (12 M HCl, 90 °C)124 100 °C (μwave), pH 3, 2 hours, 47 
μM 
97124 
TE1PA 25.5125 32 minutes (1 M HCl, 
25 °C)125 
RT, 15 minutes, 10 μM 99126 
NE3TA 
  
RT, pH 5.5, 1 minute, 1 mM 99.9127 
DE4TA 
  
RT, pH 5.5, 1 minute, 1 mM 99.6127 
L6 
  
RT, pH 5.5, 30 minutes, 30 μM 99128 
Hno1pa2py 20.96 204 minutes (3 M HCl, 
90 °C) 
RT, pH 6.5, 30 minutes, 0.1 mM 25129 
L7 
  
RT, pH 5.5, <5 minutes, 0.1 mM 100130 
NOTI 
 
30 seconds (5 M HCl, RT) RT, pH 7.4, <1 minute, 1 μM >95131 
NOTI-Me 
 
30 seconds (5 M HCl, RT) RT, pH 7.4, <1 minute, 1 μM >95131 
NOTThia 
 
55 hours (5 M HCl, 95°) RT, pH 7.4, <1 minute, 1 μM >95131 
 
 
Incorporation of a heteroatom, in the form of diphenylether, into the cross bridge 
of cyclen derivatives also results in an increase in stability to acid. The resulting Cu-
DPECB-DO2A (Fig. 6) complex has a halflife of 30.8 days in 12 M HCl at 
90 °C,132 however radiolabelling has not yet been carried out on this complex. This 
shows a significantly higher stability to acid catalysed decomplexation when 
compared to CB-DO2A which degraded in less than 2 minutes under much milder 
conditions.110 Inspired by this improvement in stability, the pycup ligand, a pyridine 
cross-bridged cyclam ligand, (Fig. 6) was assessed for its suitability in 64Cu 
chelation.117 The incorporation of pyridine into the cross bridge could potentially 
reduce the need for additional coordination sites – this would allow for 
conjugation to one of the pendant carboxylate arms without interfering with 
coordination the metal. Assessment of the acid halflife of Cu-pycup complexes 
with a varying number of acidic arms showed that these arms were not needed for 
a high stability – pycup2A which incorporated two acetic acid arms had a halflife of 
only 2.7 hours in 5 M HCl at 90 °C whereas pycup2Bn had a halflife of 20.3 hours 
under these conditions.117 All pycup derivatives tested showed high stability in rat 
plasma, and when tested in vivo showed rapid renal clearance and low uptake in 
non-target organs.117 Whilst complexation at low pH was poor, quantitative yield 
was found at 70 °C in 15 minutes at pH 7.4.117 From these studies it is apparent 
that modification of the cross bridge can be a powerful tool to improve the 
stability119 or the radiolabelling conditions117 of the resultant copper complex. 
The TRAP and NOPO ligands (Fig. 3) have been labelled with 64Cu by Simecek et 
al.120 These chelates rapidly form copper complexes and, although they were 
vulnerable to transchelation by EDTA, the chelate-copper complexes showed good 
stability in human plasma for over 12 hours.120 TRAP(CHX)3 (t1/2 = 10 h – pH 3.5, 
25 °C)65 was shown to be more kinetically stable than TRAP-Pr (t1/2 = 2 h – pH 3.5, 
25 °C).65 However in a stability study comparing TRAP(RGD)3, NOPO-RGD and 
NODAGA-RGD, NODAGA (Fig. 3) was shown to be more stable than either TRAP or 
NOPO with less than 5% transchelation over 12 hours in either EDTA or human 
plasma.120 In 0.1 M EDTA, both TRAP(RGD)3 and NOPO-RGD had more than 10% 
decomplexation over 12 hours. From this it is evident that the NOTA core forms a 
more stable copper complex than the TRAP core. 
TE1PA (Fig. 6) is a cyclam based ligand with a single picolinic acid pendant arm. This 
ligand can bind 64Cu(II) very rapidly,126 however the resulting complex is vulnerable 
to acidic conditions with a halflife of 32 minutes in 1 M HCl.125 In comparison, Cu-
cyclam has a halflife of 2.7 days in 5 M HCl despite having no pendant arms.114 A 
cross – bridged analogue, CB-TE1PA, has a significantly improved kinetic stability, 
with a halflife of 7.8 hours in 5 M HCl.133 This cross-bridged derivative has not yet 
been reported to have been radiolabelled, but the improvement in stability is 
promising for future development. 
Modification of cyclen with pendant phosphonic acid groups was undertaken by 
Simecek et al. in 2013118 to form the 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetrakis(methyl(2-carboxyethyl)phosphonic acid) (DOTPI – Fig. 5) chelate. While 
this chelate did not form a stable complex with Ga(III) (in contrast to 
TRAP),41 DOTPI readily formed a Cu(II) complex.118 The RGD conjugated chelate 
was radiolabelled with 64Cu and the resulting complex showed a high stability to 
EDTA and human plasma (99% remaining complexed after 12 h) and a high affinity 
for the αvβ3 integrin (IC50 = 73 pM, c(RGDyK) IC50 = 1330 pM).118 
Anderson and coworkers applied phosphonate pendant arms to CB-TE2A to form 
CBTE2P134 (Fig. 5) and CBTE1A1P121 (Fig. 5) with a view to overcoming the poor 
labelling kinetics of CB-TE2A whilst retaining the high stability of the resulting 
complex. This adaptation resulted in a significant improvement in radiolabelling, 
with 95% labelling at room temperature in 30 minutes. In contrast, CB-TE2A 
showed negligible labelling under the same conditions.121 Although some loss in in 
vitro stability compared to Cu-CB-TE2A was reported,121 Cu-CB-TE2P and Cu-CB-
TE1A1P both had halflives greater than 3.5 hours in 5 M HCl at 90 °C.121 Due to 
their rapid clearance from the liver, the in vivo stability of 64Cu-CB-TE2P and 64Cu-
CB-TE1A1P was reported to be high121 and this has been supported by further 
investigations of these systems using bioconjugated derivatives such as CB-
TE1K1P.135,136 
A number of derivatives of triazacyclononane (tacn) have recently been applied to 
the complexation of 64Cu. Wu and coworkers demonstrated rapid chelation of 64Cu 
with a range of bifunctional macrocyclic chelators including NE3TA and 
DE4TA.127 These chelates were successfully radiolabelled to >99.5% in less than 1 
minute at room temperature. NE3TA and DE4TA copper complexes showed high 
stability in human serum, with no decomplexation being seen over 48 hours. 
However, DE4TA was vulnerable to transmetallation by EDTA, with 44% of the 
complex being degraded over 24 hours. This instability was also seen in vivo with 
11.1% of the injected dose of 64Cu-DE4TA being retained in the liver after 24 hours 
and 5.7% in the kidneys. In contrast, 64Cu-NE3TA showed <0.2% injected dose per 
gram in all organs and blood 24 hours post-injection indicating good stability in 
vivo.127 
A recent trend has been the incorporation of heterocyclic arms to increase the 
coordination number of tacn. Bergmann and coworkers investigated a tacn 
derivative with two methylpridine arms and an acetic acid arm (L6) that was used 
to conjugate to a peptide through an amide bond. The resulting peptide conjugate 
was radiolabelled to >99% at 25 °C in 30 minutes.128 However, this complex 
showed poor stability in human blood; only 40% of the complex remained intact 
after 4 hours when a specific activity of 10 MBq μg−1 was used. When a lower 
specific activity (1 MBq μg−1) was used the stability in human blood was much 
greater – with 96% of the complex remaining intact after 24 hours in contrast to 
just 2.4% at higher activities.128 It was speculated by Bergmann and coworkers that 
this was due to saturation of the proteins that cleaved the peptide, however this 
may also lead to saturation of the desired receptor in vivo. 60 minutes after 
injection a low liver and kidney activity was reported, with 3.5% retention in the 
kidneys and 1.2% in the liver of rats.128Roger and coworkers developed a similar 
ligand, Hno1pa2py, with a methylpicolinic acid arm in place of acetic acid.129 This 
ligand can complex 100% of the 64Cu present in solution after 30 minutes at room 
temperature and neutral pH in ammonium acetate buffer. However, only 25% of 
the activity can be assigned to the expected complex using radio-HPLC with the 
remaining activity being due to two other species. HPLC analysis of the cold 
complexation mixture showed the formation of two species – possibly due to the 7 
potential coordination sites of the ligand resulting in different conformations of 
the resulting complex as Cu(II) will typically only accept 6 donors.129 Interestingly, 
the majority of the activity after radiolabelling with 64Cu (60%) was due to a species 
not seen in the cold experiment. This may be due to the relatively low copper 
concentration under radiolabelling conditions, or due to the formation of hydroxyl 
radicals by radiolysis which would not be present during “cold” complexation 
(Table 8).129 
Table 8 Stability and RCY for non-macrocylic 64Cu chelators 
Chelator Log KCu-L Acid halflife Labelling conditions RCY 
H2dedpa 19.1683 <5 minutes (6 M HCl, 90 °C)83 RT, pH 5.5, 10 minutes, 10 μM 9983 
H2azapa 
  
RT, pH 5, 10 minutes, 182 mM 9987 
L8 16.56137 
 
RT, pH 5.5, 1 minute, 0.2 μM 100138 
L9 
  
RT, pH 5.5, 1 minute, 0.2 μM 100138 
L10 18.31137 
 
RT, pH 5.5, 1 minute, 0.2 μM 100138 
L11 
  
RT, pH 5.5, 1 minute, 0.2 μM 100138 
L12 
  
RT, pH 5.5, 1 minute, 0.2 μM 100138 
L13 
  
RT, pH 5.5, 1 minute, 0.2 μM 100138 
L14 
  
50 °C, pH 5.5, 30 minutes, 2 mM 94139 
L15 
  
50 °C, pH 5.5, 30 minutes, 2 mM 93139 
L16 
  
50 °C, pH 5.5, 30 minutes, 2 mM 96139 
 
 
Viehweger and coworkers used “click” chemistry to conjugate a pyridyl 
functionalised tacn unit to a peptide (L7);130 this route was selected to simplify the 
conjugation procedure and to remove the need for protection and deprotection 
during this step. Whilst the chelate required less than 5 minutes to achieve 100% 
radiolabelling, the peptide conjugate was 100% labelled in 30 minutes.130 After 24 
hours in the presence of a 20 fold excess of TETA, >95% of the radiolabelled 
complex remained. The radiolabelled peptide conjugate was quite stable to human 
serum – with only 6% 64Cu decomplexed over 2 hours at 37 °C and 16% over 24 
hours.130 
Gotzmann and coworkers incorporated imidazole and thioimidazole arms into tacn 
to develop a rapid chelator for copper-64.131 These arms were selected due to the 
complex formation constants of the free imidazole with copper in contrast to that 
of acetic acid – imidazole has a log β1 = 4.21 whereas acetic acid has log β1 = 1.79, 
this indicates that a tacn ligand incorporating imidazole arms will have more 
favourable complex formation than NOTA. Of the three ligands tested by 
Gotzmann and coworkers, NOTThia, which incorporates thiazole arms, was the 
best. All three ligands showed very rapid complexation at room temperature and a 
range of pH values131 and showed a high stability to transmetallation with natural 
abundance copper (<2% decomplexation of 64Cu over 24 hours in the presence of 
5-fold natural abundance copper).131 When assessed in human serum, each ligand 
showed some instability with approximately 10% decomplexation occurring over 
24 hours. NOTThia outperformed the two imidazole based ligands when exposed 
to 5 M hydrochloric acid – the thiazole complex had a halflife of 55 hours at 95 °C 
whereas the two imidazole based ligands had halflives of 30 seconds at room 
temperature.131 This is likely due to the low pKa of thazole (2.80) in comparison to 
the imidazole units (7.00–7.10) resulting in less protonation of the thiazole at low 
pH values and therefore a more stable complex. All three 64Cu complexes were 
retained to a degree in the kidneys of mice, with a 40% retention of 64Cu-NOTI 
after 40 minutes. This retention was greater than that of non-chelated 64Cu 
indicating that it is the complex being retained and not due to the release of the 
metal. In contrast the retention of the complexes in the liver is slightly lower than 
that of free 64Cu 45 minutes post injection, with only 11% of NOTI being retained 
whereas 17% of free copper was retained. This retention may be due to the overall 
positive charge of the complex in contrast to the negatively charged NOTA and 
DOTA complexes which are cleared from both organs.131 
The successes seen when adapting CB-TE2A to CB-TE1A1P and CB-TE2P were not 
mirrored when Yoo and coworkers attempted to improve upon the radiolabelling 
conditions of the highly stable PCB-TE2A.119 Whilst Cu-PCB-TE1A1P122 and Cu-PCB-
TE2P123 both displayed a high stability under acidic conditions (Table 7), neither 
ligand significantly improved upon the high temperatures required for 
radiolabelling PCB-TE2A with 64Cu(II).122,123 
3.2.2. Non-macrocylic 64Cu chelators. Orvig and coworkers applied H2dedpa to the 
complexation of 64Cu.83 As expected for an acyclic ligand, the radiolabelling 
conditions required were relatively mild – proceeding at room temperature and pH 
5.5 – and a quantitative yield was rapidly achieved.83 However the resulting 
complex had poor kinetic stability, degrading in 6 M HCl with a halflife less than 5 
minutes.83 Orvig and coworkers incorporated an alkyne into the H2dedpa ligand to 
facilitate bioconjugation through a catalysed azide–alkyne “Click” reaction.87 To 
establish the stability of metal complexes formed with ligands conjugated in this 
way, benzyl azide was used to form the ligand H2azapa.87 During the conjugation 
reaction it was noted that an excess of copper was needed due to complexation of 
Cu(II) ions by the ligand. After removal of the Cu(II) ions the H2azapa ligand was 
obtained and the stability of the copper complex that resulted was tested. 
Radiolabelling of H2azapa was successful, although significantly higher 
concentrations of ligand (182 mM) were needed87 when compared to H2dedpa (10 
μM).83 
Comba and co-workers reported a range of bispidine chelates (Fig. 7) that could 
complex 64Cu(II) extremely rapidly at room temperature (Table 8).140 These 
chelates also showed a high stability to transchelation by cyclam in a competition 
study140 – L8 retained 81% of the 64Cu after 2 hours and 30% after 24 hours when 
incubated with 80 equivalents of cyclen, but L13 retained 99% even after 24 hours 
incubation.140 Overall the pentadentate chelates were shown to be more stable 
than their tetradentate counterparts to transchelation by cyclen.140 In addition, the 
reduction of the bridging ketone to an alcohol improved the stability to 
transchelation – it was suggested that this prevented a reverse Mannich reaction 
which would cause the complex to decompose.140 The stability of a number of 
these Cu-bispidine complexes were also tested against superoxide dismutase and 
in human serum.139 80% of the Cu-L10 complex remained intact after an hour in 
human serum, however the p-OMe derivative L11 formed a complex that showed a 
greater stability – with 96% remaining intact over an hour.139 This trend was also 
seen in the transchelation studies previously mentioned.140 These complexes also 
displayed very rapid radiolabelling kinetics – with labelling being completed in 
under a minute at room temperature for L8–L13.140 
 
 
 Fig. 7 Bispidines applied to copper chelation.  
Adaptation of bispidines to be incorporated into macrocycles significantly 
hampered the radiolabelling kinetics. L14, L15 and L16 (Fig. 7), all required heating to 
50 °C to achieve a high radiochemical yield, with reaction times in excess of 30 
minutes in each case.139However, L16 was stable to superoxide dismutase and 
human serum, retaining 98.5 and 97.7% of the 64Cu respectively after 1 hour in 
solution.139 
Charbonnière and co-workers developed a pair of highly stable bispidine 
compounds – L15 and L16 (Fig. 7) – that showed extremely long copper-complex 
half-lives under acidic conditions.141 These compounds have the same core as 
those described by Comba and co-workers,140 with the pendant arms being varied 
to a carboxylic acid and a thiofuran. The 71 day halflife of Cu-L15 under acidic 
conditions141 demonstrates that it is kinetically inert, although radiolabelling has 
not yet been reported with this compound. 
3.3. The future development of 64Cu chelators 
The development of chelators such as PCB-TE2A119 for copper chelation which 
display a high kinetic stability is extremely promising for the future development of 
this field. Due to its long halflife, 64Cu is well suited to longer studies involving 
targeting motifs with a longer biological halflife, such as antibodies. As a result, the 
copper-chelate complex formed needs to be highly stable in vivo. It is apparent 
that a cross-bridged cyclam motif is the most ideal form tested so far – and that 
adaptations of the cross bridge can produce highly stable complexes, such as PCB-
TE2A and DPE-CB-DO2A. Further investigation into these chelates to further 
improve upon their radiolabelling conditions will be a key area of research for the 
development of copper chelates of the future. 
Comba and coworkers reported bispidine ligands that rapidly 
complexed 64Cu,140 whereas Charbonnière and coworkers have reported highly 
stable Cu-bispidine complexes.141 This class of chelator has not yet been widely 
explored for 64Cu chelation but these early reports are highly promising. 
The longer halflife of 64Cu in comparison to 68Ga and 18F is more forgiving during 
the radiolabelling step; mild conditions that are tolerable by a wider range of 
targeting motifs is of a higher priority than extremely short complexation times. 
Significant progress has been made with respect to this goal – the development of 
CB-TE2P by Anderson et al. provides a clear example of how this goal may be 
achieved for other chelates in the future – careful selection of coordinating arms 
can lead to the optimisation of the complexation properties, for example 
improving the radiolabelling conditions without sacrificing stability of the resulting 
complex. 
4. Zirconium-89 
With a halflife of 3.3 days, 89Zr offers very different decay properties to 68Ga 
and 64Cu.9 This longer halflife lends itself to techniques such as antibody based 
imaging where the biological lifetime is also several days.14289Zr is produced using a 
cyclotron, this longer halflife also makes it more practical to transport the 
radioisotope from an external site if the scanning location does not have access to 
a cyclotron.143 
Zr(IV) has complex aqueous chemistry, with a number of polynuclear species being 
formed144,145 and poor solubility except at extreme pH values.146 Weakly 
coordinated 89Zr(IV) has been shown to have an affinity for bones and joints,147 and 
was also seen to accumulate in the liver under some conditions.147,148 Zr(IV) will 
typically have a coordination number of 8.8,149 
4.1. Deferoxamine B 
The majority of studies involving the chelation of 89Zr use the siderophore 
deferoxamine B (DFO – Fig. 8) as the chelator.148,150–15889Zr-DFO showed good 
stability in vivo,159–162 although recent studies have reported some bone uptake in 
mouse studies.148,150,153This instability is dependent on the method of conjugating 
DFO to the targeting motif – Tinianow and coworkers reported a 10.7% 
decomplexation over 6 days of 89Zr from a DFO complex where conjugation to 
trastuzumab was achieved through a CHX-maleimide linker,153 whereas Zeglis and 
coworkers reported a 15.1% decomplexation over 5 days when a 
tetrazine/norbornene coupling reaction was used for conjugation to 
trastuzumab.15089Zr-DFO has even been applied in man,163,164 the successes of this 
ligand make it the prevailing choice for chelation of 89Zr.  
  Fig. 8 Structures of zirconium chelators.  
Perk and coworkers achieved a 60% RCY when radiolabelling a DFO bioconjugate 
with 89Zr in HEPES buffer.164 In contrast, when using DTPA conjugated to the same 
antibody less than 0.1% labelling was observed.164 Ma and coworkers achieved a 
98% RCY when radiolabelling DFO in an ammonium acetate buffer (Table 9).159 
Table 9 Radiolabelling conditions and stability for 89Zr chelates 
Chelate Radiolabelling conditions RCY 
DFO RT, pH 7, 10 minutes, 1 mM 98159 
DFO* RT, pH 7, 2 hours, 3 μM 100165 
Chelate Radiolabelling conditions RCY 
HOPO RT, pH 7, 10 minutes, 10 mM 100162 
Linear tetrahydroxamate n = 5 80 °C, pH 7, 30 minutes, 150 μM 87161 
Linear tetrahydroxamate n = 6 RT, pH 7, 2 hours, 150 μM 95161 
Linear tetrahydroxamate n = 7 RT, pH 7, 2 hours, 150 μM 99161 
Cyclic tetrahydroxamate n = 5 80 °C, pH 7, 30 minutes, 150 μM 29161 
Cyclic tetrahydroxamate n = 6 50 °C, pH 7, 30 minutes, 150 μM 92161 
Cyclic tetrahydroxamate n = 7 RT, pH 7, 2 hours, 150 μM 99161 
DMTP1 RT, pH 7, 15 minutes, 60 μM 100160 
DMTP2 RT, pH 7, 15 minutes, 60 μM 100160 
CP256 RT, pH 6.5, 10 minutes, 1 mM 99%159 
FSC RT, pH 7, 90 minutes, 58 μM 100166 
DTPA RT, pH 7, 60 minutes 0.1164 
H6Phospha 37 °C, pH 7, 18 hours 12167 
 
 
 
4.2. Alternative 89Zr chelators 
While Zr(IV) can accommodate up to 8 ligands in its coordination sphere, DFO 
occupies only 6 coordination sites. This has been speculated to be the cause of 
observed instability. An extended derivative of DFO, DFO* (Fig. 8) has been 
synthesised and tested for its 89Zr chelation ability.165 A peptide conjugate of DFO* 
was quantitatively radiolabelled at room temperature and pH 7 in 2 hours. The 
DFO* complex remains largely intact after 24 hours in the presence of 3000 fold 
excess DFO (90% of the 89Zr remaining complexed by DFO*) showing that fully 
occupying the coordination sphere of zirconium can improve the stability of the 
resultant complex.165 
10 mM HOPO (Fig. 8) was used to achieve quantitative radiolabelling with 89Zr 
within 10 minutes at room temperature at pH 7.162 However, as the concentration 
of the ligand was decreased, the complexation time increased. 10 μM of HOPO 
took 45 minutes to achieve quantitative complexation. The resultant 89Zr-HOPO 
complex was extremely stable to transmetallation by EDTA, remaining completely 
intact when incubated with a 100 fold excess of EDTA across a range of pH values 
from 5–8 for over 7 days. The complex was also stable to transchelation by a range 
of metals, with iron being the notable exception with 17% of the 89Zr being 
transchelated. No significant bone uptake (1%) of 89Zr was seen over 24 hours in 
mice, and the complex underwent excretion via renal and hepatobiliary routes. 
The crystal structure of zirconium with bidentate hydroxamates reveals that Zr(IV) 
forms an octacoordinated complex with 4 coordinated bidentate ligands.149 As a 
result of this structure, a series of linear and cyclic tetrahydroxamic acid chelates 
were developed by Guérard and coworkers for the complexation of 
zirconium.161 Unlike DFO, which has only 6 coordinating sites, these ligands would 
have 8 sites and therefore should form more stable complexes with Zr(IV). The 
length of the spacers between the coordination sites was varied to discern the 
optimum length – in this study it was found that a spacer length of 7 was more 
stable than one of 5.161 The poor solubility of the complexes formed limited the 
characterisation that could be performed – however studies that made use of the 
radioactive 89Zr isotope allowed for binding and stability studies to be performed. It 
was found that the largest cyclic tetrahydroxamic acid chelate could bind 89Zr with 
a 92% RCY in 30 minutes at room temperature and pH 7, with a 99% yield after 2 
hours. The smaller tetrahydroxamic acid ligands tested had reduced success at 
binding 89Zr, although the linear analogues generally were more successful than 
the cyclic chelates. All chelates tested were stable to human serum and PBS over a 
7 day period, but in the presence of concentrated EDTA the Zr(IV) was 
decomplexed to a degree for all systems tested. Both the cyclic and linear systems 
with a spacer length of 7 were more stable than DFO in the presence of EDTA 
(87%, 79% and 47% remaining after 7 days respectively). As expected, increasing 
the number of coordination sites improved the stability of the resulting zirconium 
complex.161 
Blower et al. applied CP256 (Fig. 4) to the chelation of 89Zr.159 It was seen that 
CP256 formed a complex rapidly at room temperature and pH 6.5, with a 99% RCY 
at chelator concentrations above 1 mM. Below this concentration the labelling was 
significantly slower, at 100 μM it took 60 minutes to achieve a 9% RCY. 
Competition studies of CP256 with DFO showed that the complex formed was 
stable to transmetallation, with limited exchange to DFO when added to a 89Zr-
CP256 sample and rapid transmetallation when CP256 was added to a 89Zr-DFO 
sample. In contrast, the CP256 complex was vulnerable to transchelation of 
the 89Zr by Fe(III). When in a 10 : 1 [Fe] : [Zr-L] ratio, 86% of the Zr(IV) dissociated 
from the CP256 complex whereas only 7% dissociated from DFO. This is important 
as iron will be present in the body in much higher concentration than the complex 
when applied as a radiotracer. Testing of the CP256 complex in vivo showed that it 
rapidly cleared from the blood pool via a renal pathway. A bio-conjugated 
derivative of CP256, YM310-trastuzamab was labelled with 89Zr and tested further. 
This system showed high stability in human serum, with >95% stability after 7 days. 
When tested in vivo in mice, however, the YM103-trastuzamab complex showed 
poorer stability, with 29.0% skeletal uptake being seen after 3 days.161 
The success of the siderophore DFO inspired Decristoforo et al. to investigate the 
siderophore fusarine C (FSC).166 The cyclic nature of this siderophore was expected 
to increase the stability of the resultant complex when compared to DFO. 
Radiolabelling in HEPES buffer at room temperature and neutral pH of FSC-RGD 
conjugates resulted in quantitative labelling with 89Zr in 90 minutes at a 
concentration of 58 μM, and in 30 minutes at higher concentrations. The 89Zr-FSC-
RGD complexes showed high stability in PBS and human serum over a period of 7 
days with no transmetallation being reported. In a solution containing 1000 fold 
excess EDTA, 89Zr-FSC-RGD showed less than 6% transchelation over 7 days at pH 
7. In contrast, 89Zr-DFO showed nearly 60% transchelation by EDTA after 7 days. 
This indicates a much greater stability of FSC than DFO, highlighted in a 
competition study in which 100% transchelation of Zr-DFO occurred in the 
presence of 1000 fold FSC after 7 days, but only 40% when the ratios were 
reversed.166 
A pair of large di-macrocyclic terephthalamide ligands were synthesised for 
zirconium chelation.160 These chelates achieved quantitative labelling in 15 
minutes at room temperature and neutral pH. In addition, the radiolabelling of 
these chelates was achieved at a much lower concentration of ligand than the 
radiolabelling of DFO. The resultant complex was highly stable in human serum 
over 7 days, and also stable to 50 mM DTPA at pH 7 for 7 days. 89Zr-DFO was nearly 
60% decomplexed under the same conditions.160 
4.3. Future development of zirconium-89 chelators 
Overall, chelation of 89Zr has leapt forward over the last 5 years – going from just 
one recognised chelator to a range of alternative chelator systems. Further 
improvement of complexation times and complex stability can be expected, and 
further in vivo testing of those chelates that have been shown to be effective will 
cement their role for the future. 
It is apparent that the use of cyclic chelators, and of occupying all 8 coordination 
sites of zirconium, are key to producing a highly stable complex. While both 89Zr-
DFO* and 89Zr-FSC showed improved stability when compared to 89Zr-DFO, their 
extended radiolabelling times may limit their future use. However, the two 
dimacrocylic terephtalamide ligands DMTP1 and DMTP2 have improved 
radiolabelling and stability properties when compared to DFO.160 These ligands are 
highly promising and further studies into their in vivobehaviour will reveal whether 
or not they can truly compete with DFO as a chelator for 89Zr. 
5. Scandium-44 
44Sc is a positron emitting isotope which has great potential. With a halflife of 3.9 
hours, 44Sc can be used to study longer biological processes than 68Ga. In addition 
to this, another isotope of scandium, 47Sc, emits β− and can be used as a 
therapeutic agent for treatment of cancers. The combination of these two isotopes 
would make a powerful medicinal tool as the distribution of the therapeutic agent 
could be followed exactly through the use of the PET agent. 
44Sc can be produced from either a generator or a cyclotron source. Generator 
produced 44Sc is eluted from 44Ti (halflife = 59 years) using an ammonium acetate 
solution.168 Cyclotron produced 44Sc is produced from a 44Ca target.169,170 This 
variety of production methods makes scandium a versatile radiometal that could 
be widely used in the future, with the source being selected according to the user's 
requirements. 
Scandium has a flexible coordination number, complexes with coordination 3 to 9 
have been reported, although octahedral 6 coordinate complexes are the most 
common structure reported.171,172 The chelation of scandium has not, until 
recently, been widely explored. Since 2012 a number of papers have been 
published exploring the chelation of 44Sc by common chelators. 
5.1. 44Sc chelators 
DOTA and its derivatives have been applied to scandium and form stable 
complexes (log KSc-DOTA = 27.0) that remain stable to human serum over extended 
periods of time.173 However, labelling requires heating and extended reaction 
times12 – Majkowska-Pilip et al.reported labelling requiring temperatures of 70 °C 
and a labelling time of 30 minutes.173 Labelling at room temperature was shown to 
be possible, although it required labelling times of over 24 hours.173 NOTA was 
labelled significantly faster under these conditions, although the less stable 
complex formed resulted in a lower final yield of only 80%.173 The 44Sc-NOTA 
complex formed was stable to human serum, although not to PBS due to the 
phosphate ions binding in place of the NOTA ligand.173 Multiple studies have been 
carried out with 44Sc-DOTA type complexes in vivo, these show that the complex is 
highly stable and shows good specificity for its targets.12,174–177 
Acyclic chelators have been shown to bind scandium more rapidly than 
DOTA,178,179 although some chelators showed reduced stability when compared to 
cyclic chelators (Fig. 9).179 CHX-A′′-DTPA, DTPA and EGTA (Table 10) were all shown 
to be viable options for chelation of scandium. DTPA and EGTA achieved 
quantitative chelation at room temperature and the resulting complexes showed a 
high stability to PBS.179 CHX-A′′-DTPA (Table 10) achieved an 80% RCY in 30 
minutes at pH 4.5 at room temperature.178 When CHX-A′′-DTPA was conjugated to 
a cetuximab-fab fragment the yield fell to 66%. DOTA-cetuximab-fab achieved only 
a 21% RCY under these conditions, and NOTA-cetuximab-fab only a 14% 
yield.178 The resulting 44Sc-CHX-A′′-DTPA complex showed high stability to mouse 
serum, with 92% of the complex remaining intact after 6 hours incubation.178 
 
 
 Fig. 9 Acyclic scandium chelators.  
Table 10 Radiolabelling conditions for 44Sc chelators 
Chelator Log KML Labelling conditions RCY/% 
DOTA 27.0173 90 °C, pH 4.5, 15 minutes, 10 μM 97.712 
NOTA 16.5173 70 °C, pH 6, 30 minutes 80173 
CHX-A′′-DTPA — RT, pH 4.5, 30 minutes, 1.6 μM 80178 
DTPA — RT, pH 6, 10 minutes 100179 
EGTA — RT, pH 6, 10 minutes 97.2179 
 
 
 
5.2. Future development of 44Sc chelators 
Overall, the limited development of 44Sc chelators has shown that this radiometal 
has potential, with stable complexes formed under mild conditions. Macrocyclic 
chelators like DOTA have been shown to be able to bind 44Sc, although these 
macrocyclic ligands require high temperatures for radiolabelling. CHX-A′′-DTPA is 
an example of a chelator which will rapidly form complexes with scandium and 
appears to have a high stability. However, the stability of the 44Sc-CHX-A′′-DTPA 
complex has only been tested for 2 halflives – the complex will need to be stable 
for longer periods of time to be widely used in medical applications. 
Development of the chelation of 44Sc could be expanded through the application of 
many of the chelates discussed above. The chelates described here all contain a 
mixture of amine and acetic acid units – the use of alternate coordinating arms can 
change the radiolabelling kinetics and stability of the resulting complex 
significantly. The stability of 44Sc-DOTA suggests that derivatives of this system 
would be a good starting point for future development. 
Alternatively, stable acyclic chelate complexes could become the focus of 
development – the applicability of CP256 to both 68Ga and 89Zr complexation may 
translate to successful 44Sc complexation. 
6. Conclusions 
The trend towards shorter complexation times, under milder conditions has been 
apparent across the radiometals investigated and looks set to continue into the 
future, with effective labelling using lower ligand concentrations being an 
extension of this aim. 
Due to its generator based production, 68Ga is set to become a widely used and 
readily accessible radionuclide for PET. The variety of acyclic chelators tested for 
their ability to complex 68Ga reflects the importance of rapid chelation for this 
radionuclide due to its relatively short halflife (68 minutes). Of the recently 
reported acyclic chelators CP256,45 AAZTA91 and H2dedpa4 stand out for their mild 
and rapid radiolabelling conditions – and of these CP256 displays a particularly high 
stability to transchelation by transferrin which makes it promising for future 
development. 
The longer halflife (12.7 hours), of 64Cu in comparison to 68Ga and 18F is more 
forgiving during the radiolabelling step; a highly stable 64Cu complex and mild 
conditions that are tolerable by a wider range of targeting motifs are of a higher 
priority than extremely rapid complexation kinetics. Significant progress has been 
made with respect to this goal – the development of CB-TE2P by Anderson et 
al.121 provides a clear example of how this goal may be achieved for other chelates 
in the future. A measure of success has been with the bispidine species alongside 
modified cross-bridged species such as PCB-TE2A119 and DPE-CB-TE2A132 as the 
most successful chelates for 64Cu. Once a satisfactory stability is achieved, the next 
aim for 64Cu chelation would be to improve its complexation kinetics to improve 
the specific activity achieved and to reduce exposure of workers to unnecessary 
radiation. In this context PCB-TE2A119 improves upon CB-TE2A but still requires 
harsh reaction conditions – however CB-TE2P121 achieves almost quantitative 
complexation of64Cu at room temperature in 30 minutes at ligand concentrations 3 
orders of magnitude lower than that required for CB-TE2A. 
Research into coordination of 89Zr has leapt forward over the last 5 years – going 
from just one recognised chelator to a range of alternative chelator systems. With 
its extremely long half live rapid chelation kinetics do not need to be prioritise, 
kinetic and thermodynamic stability of the complex is key along with a specific 
targeting motif for imaging. Further improvement of complexation times and 
complex stability can be expected, and further in vivo testing of those chelates that 
have been shown to be effective will cement their role for the future. 
It is apparent that the use of cyclic chelators, and occupying all 8 coordination sites 
of zirconium, are key to producing a highly stable complex. While both 89Zr-DFO* 
and 89Zr-FSC showed improved stability when compared to 89Zr-DFO, their 
extended radiolabelling times may limit their future use. However, the two 
dimacrocylic terephtalamide ligands DMTP1 and DMTP2 have improved 
radiolabelling and stability properties when compared to DFO.160 These ligands are 
highly promising and further studies into their in vivobehaviour will reveal whether 
or not they can truly compete with DFO as a chelator for 89Zr. In addition to its 
success at complexation of 68Ga, CP256 has already been further applied to the 
complexation of another radiometal; 89Zr.159 This ligand's versatility was 
demonstrated as it again formed a stable complex rapidly at room temperature – 
although the 89Zr-CP256 complex formed was vulnerable to transmetallation by 
Fe3+ ions. 
44Sc is a positron emitting isotope which has great potential. With a halflife of 3.9 
hours, 44Sc can be used to study longer biological processes than 68Ga. The success 
of traditional chelators at complexing scandium suggests that this will be a field 
that is ripe for development – much of the progress that has been seen for the 
other radiometals could be replicated using 44Sc to produce a PET tracer with a 
half-life that is between 68Ga and 64Cu, potentially increasing the flexibility of PET as 
a diagnostic technique. 
Each of these radiometals have specific properties such as coordination geometry 
and halflife which should be considered when designing a new ligand system. This 
field is ever expanding and at an exciting juncture with significant advances in 
ligand design for Positron Emission Tomography Imaging. 
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